Valuation: Kamada Ltd.

Market Cap 1.23B 0 410M 355M 333M 303M 571M 39.1B 581M 3.9B 1.53B 19.57B 1.54B 1.51B 65.3B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.23B 0 410M 355M 333M 303M 571M 39.1B 581M 3.9B 1.53B 19.57B 1.54B 1.51B 65.3B EV / Sales 2026 *
2.05x
EV / Sales 2027 * 1.88x
Free-Float
54.51%
Yield 2026 *
-
Yield 2027 * -
1 day-1.69%
1 week-3.68%
Current month-5.85%
1 month-2.97%
3 months-14.53%
6 months-18.71%
Current year-7.35%
1 week 2,013
Extreme 2013
2,209
1 month 2,013
Extreme 2013
2,260
Current year 2,013
Extreme 2013
2,890
1 year 1,956
Extreme 1956
2,890
3 years 1,685
Extreme 1685
3,045
5 years 1,309
Extreme 1309
3,045
10 years 1,309
Extreme 1309
4,500
Manager TitleAgeSince
Chief Executive Officer 57 30/06/2015
Director of Finance/CFO 55 30/12/2017
Chief Operating Officer 53 31/10/2016
Director TitleAgeSince
Director/Board Member 75 12/12/1990
Chairman 77 06/03/2013
Chairman 55 11/08/2020
Date Insider Type Main position Quantity % Market Cap.
05/08/26 Free

Director

30,000 0.0520%
05/08/26 Free

Chairman

30,000 0.0520%
05/08/26 Free

Director

30,000 0.0520%
Change 5-day change 1-year change 3-year change Capi.($)
-2.68%-3.68%-17.23%+9.69% 410M
-0.05%+3.08%+42.35%-1.99% 79.58B
+2.55%+9.01%+1.40%+30.65% 52.73B
-1.41%-2.53%+19.43%+171.97% 49.77B
+0.08%+5.95%-47.62%-47.36% 46.77B
+0.12%-1.77%+57.42%-25.58% 30.13B
-0.44%+0.35%+47.31%+84.27% 24.54B
+2.24%+8.88%+138.70%-38.75% 24.18B
0.00%+5.81%+9.45%+194.91% 21.2B
-0.08%+1.81%+70.03%+164.56% 16.36B
Average +0.26%+3.58%+32.12%+54.24% 34.57B
Weighted average by Cap. +0.39%+4.49%+28.26%+43.36%

Financials

2026 *2027 *
Net sales 600M 0 200M 174M 162M 148M 279M 19.1B 284M 1.91B 747M 9.56B 752M 736M 31.9B 655M 0 218M 189M 177M 162M 304M 20.83B 309M 2.08B 814M 10.43B 820M 802M 34.78B
Net income 73.89M 0 24.66M 21.37M 20M 18.25M 34.35M 2.35B 34.92M 235M 91.9M 1.18B 92.58M 90.56M 3.93B 105M 0 35.18M 30.49M 28.54M 26.04M 49M 3.36B 49.83M 335M 131M 1.68B 132M 129M 5.6B
Net Debt - -
Logo Kamada Ltd.
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Employees
462
Date Price Change Volume
12/08/26 ILA 2,073.00 -2.68% 600,804
11/08/26 ILA 2,130.00 -0.65% 46,917
10/08/26 ILA 2,144.00 +0.09% 72,155
07/08/26 ILA 2,142.00 +1.52% 23,568
06/08/26 ILA 2,110.00 -2.94% 132,837
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KMDA Stock